. Author manuscript; available in PMC: 2019 Nov 11.

Published in final edited form as: Diabetes Res Clin Pract. 2014 Oct 23;107(2):280–289. doi: 10.1016/j.diabres.2014.10.007

Table 3 –

The role of DCCT-severe hypoglycemia in atherosclerosis for patients with A1C_DCCT/EDIC < 7.5% and A1C_DCCT/EDIC ≥ 7.5% (CAC ≥ 100).

Clinical factor of interest in model	A1C_DCCT/EDIC < 7.5%				_DCCT/EDIC ≥ 7.5%
	Model 1^a		Model 2^b		Model 1^a
	RR(95%CI)	p	RR(95%CI)	p	RR(95%CI)	p
DCCT-severe hypoglycemia rate	1.34(1.07–1.68)	0.009	1.30(1.04–1.64)^c	0.02	1.03(0.86–1.23)	0.76
DCCT-ACI	0.93(0.51–1.68)	0.79	1.08(0.58–2.01)	0.82	1.18(1.03–1.36)	0.02

Model 1: baseline age, gender, DCCT-A1C, DCCT-severe hypoglycemia rate.

Model 2: baseline age, gender, DCCT-A1C, DCCT-severe hypoglycemia rate, baseline diabetes duration, baseline neuropathy, baseline-AER, smoking status, LDL-cholesterol, systolic blood pressure, BMI and DCCT-A1C. Since p-values for baseline hypoglycemia, group treatment and baseline retinopathy were large, these factors were not included in model.

Scanning site or Eligibility-HbA_1C instead of DCCT-A1C did not significantly modify the relationship between severe hypoglycemia and CAC.